Compared to BET-inhibitors (JQ1 or OTX015), BET-PROTACs treatment (ARV-771 or ARV-825) induced more perturbations in gene expression, and have shown promising anti-tumor activity in multiple malignancies including DLBCL [123,125]. The gene discussed is DNER; the disease is diffuse large B-cell lymphoma.